CY1120826T1 - Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης - Google Patents
Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασηςInfo
- Publication number
- CY1120826T1 CY1120826T1 CY181101172T CY181101172T CY1120826T1 CY 1120826 T1 CY1120826 T1 CY 1120826T1 CY 181101172 T CY181101172 T CY 181101172T CY 181101172 T CY181101172 T CY 181101172T CY 1120826 T1 CY1120826 T1 CY 1120826T1
- Authority
- CY
- Cyprus
- Prior art keywords
- benzotriazole derivatives
- formula
- present
- tripplocated
- biphidororotic
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 title 1
- 150000001565 benzotriazoles Chemical class 0.000 title 1
- 229910052760 oxygen Inorganic materials 0.000 title 1
- 239000001301 oxygen Substances 0.000 title 1
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 abstract 2
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 abstract 2
- 125000003354 benzotriazolyl group Chemical class N1N=NC2=C1C=CC=C2* 0.000 abstract 2
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003650 oxygenase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση προτείνει τριυποκατεστημένα παράγωγα βενζοτριαζόλης ως ενώσεις αναστολής της διυδροοροτικής οξυγενάσης του τύπου (I), οι οποίες μπορεί να είναι θεραπευτικά χρήσιμες ως αναστολείς DHODH. (I) όπου, τα R1, R2, και R3 έχουν τις έννοιες που δίδονται στις προδιαγραφές του διπλώματος ευρεσιτεχνίας, και φαρμακευτικά αποδεκτά άλατα αυτών τα οποία είναι χρήσιμα στην θεραπεία και πρόληψη ασθενειών ή παθήσεων όπου είναι επωφελής η αναστολή της DHODH. Η παρούσα εφεύρεση προτείνει επίσης μεθόδους σύνθεσης τριυποκατεστημένων παραγώγων βενζοτριαζόλης του τύπου (I). Η παρούσα εφεύρεση προτείνει επίσης φαρμακευτικές συνθέσεις περιλαμβάνουσες μία τουλάχιστον εκ των ενώσεων αναστολής DHODH του τύπου (I) μαζί με έναν φαρμακευτικά αποδεκτό φορέα, αραιωτικό μέσο ή έκδοχο.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN825CH2013 | 2013-02-25 | ||
| PCT/IB2014/059204 WO2014128669A2 (en) | 2013-02-25 | 2014-02-24 | Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120826T1 true CY1120826T1 (el) | 2019-12-11 |
Family
ID=51391932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY181101172T CY1120826T1 (el) | 2013-02-25 | 2018-11-07 | Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9630932B2 (el) |
| EP (2) | EP3019482B1 (el) |
| CY (1) | CY1120826T1 (el) |
| DK (1) | DK3019482T3 (el) |
| ES (1) | ES2694829T3 (el) |
| HR (1) | HRP20181908T1 (el) |
| HU (1) | HUE042032T2 (el) |
| LT (1) | LT3019482T (el) |
| PL (1) | PL3019482T3 (el) |
| PT (1) | PT3019482T (el) |
| RS (1) | RS57962B1 (el) |
| SI (1) | SI3019482T1 (el) |
| WO (1) | WO2014128669A2 (el) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE042032T2 (hu) | 2013-02-25 | 2019-06-28 | Aurigene Discovery Tech Ltd | Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak |
| WO2018038886A1 (en) * | 2016-08-23 | 2018-03-01 | Icahn School Of Medicine At Mount Sinai | Methods for treating pten-mutant tumors |
| CN114921391B (zh) | 2016-10-27 | 2024-01-02 | 拜耳股份有限公司 | 4,5-环状1,2,4-三唑酮 |
| EP3585772B1 (en) * | 2017-02-24 | 2023-10-11 | Merck Patent GmbH | 1, 4, 6-trisubstituted-2-alkyl-1h-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitors |
| US20180369206A1 (en) * | 2017-04-24 | 2018-12-27 | Aurigene Discovery Technologies Limited | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors |
| HUE056485T2 (hu) * | 2017-04-24 | 2022-02-28 | Aurigene Discovery Tech Ltd | Eljárások háromszorosan szubsztituált benzotriazol-származékok alkalmazására dihidroorotát-oxigenáz inhibitorokként |
| CA3091792A1 (en) | 2018-02-20 | 2019-08-29 | Agios Pharmaceuticals, Inc. | Methods of use for trisubstituted benzotriazole derivatives |
| SG11202012029PA (en) | 2018-06-22 | 2021-01-28 | Ohio State Innovation Foundation | Methods and compositions for inhibition of dihydroorotate dehydrogenase |
| US11787791B2 (en) | 2018-09-28 | 2023-10-17 | Acucela Inc. | Inhibitors of VAP-1 |
| MX2021003731A (es) | 2018-09-28 | 2021-08-05 | Acucela Inc | Inhibidores de vap-1. |
| PE20212197A1 (es) * | 2018-12-21 | 2021-11-16 | Les Laboratoires Servier Sas | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo |
| WO2021262874A1 (en) | 2020-06-24 | 2021-12-30 | Servier Pharmaceuticals , Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| CA3184024A1 (en) | 2020-06-24 | 2021-12-30 | Les Laboratoires Servier | Use of a dhodh inhibitor compound in combination cancer therapy |
| WO2022047051A1 (en) | 2020-08-27 | 2022-03-03 | Servier Pharmaceuticals, Llc | Use of a dhodh inhibitor compound in combination cancer therapy |
| WO2022167402A1 (en) | 2021-02-02 | 2022-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of therapy comprising administering a therapeutically effective combination comprising a dhodh inhibitor and an idh inhibitor |
| US20240287075A1 (en) * | 2021-07-05 | 2024-08-29 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | 1,2,4-triazolone derivative as dhodh inhibitor, and preparation method therefor and use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0527736T3 (da) | 1990-05-18 | 1997-10-20 | Hoechst Ag | Isoxazol-4-carboxylsyreamider og hydroxyalkyliden-cyanoacetamider, lægemidler indeholdende disse forbindelser og anvendelsen af disse lægemidler. |
| US5904937A (en) | 1997-10-03 | 1999-05-18 | Fmc Corporation | Taste masked pharmaceutical compositions |
| US6841561B1 (en) | 1999-10-01 | 2005-01-11 | Institute Of Molecular And Cell Biology | Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| DE102005049953A1 (de) * | 2005-10-19 | 2007-04-26 | Sanofi-Aventis Deutschland Gmbh | Carbamoylbenzotriazol-derivate als Inhibitoren von Lipasen und Phospholipasen |
| WO2008028860A1 (en) * | 2006-09-08 | 2008-03-13 | F. Hoffmann-La Roche Ag | Benzotriazole kinase modulators |
| US20110275684A1 (en) * | 2009-01-19 | 2011-11-10 | Neurosearch A/S | Novel benzotriazole derivatives useful for the treatment of cns disorders |
| CN102574786A (zh) | 2009-04-02 | 2012-07-11 | 默克雪兰诺有限公司 | 二氢乳清酸脱氢酶抑制剂 |
| HUE042032T2 (hu) | 2013-02-25 | 2019-06-28 | Aurigene Discovery Tech Ltd | Triszubsztituált benzotriazol-származékok, melyek dihidro-orotát-oxigenáz-inhibitor hatásúak |
-
2014
- 2014-02-24 HU HUE14754772A patent/HUE042032T2/hu unknown
- 2014-02-24 EP EP14754772.3A patent/EP3019482B1/en active Active
- 2014-02-24 LT LTEP14754772.3T patent/LT3019482T/lt unknown
- 2014-02-24 SI SI201430904T patent/SI3019482T1/sl unknown
- 2014-02-24 EP EP18185083.5A patent/EP3417850A1/en not_active Withdrawn
- 2014-02-24 PT PT14754772T patent/PT3019482T/pt unknown
- 2014-02-24 RS RS20181322A patent/RS57962B1/sr unknown
- 2014-02-24 WO PCT/IB2014/059204 patent/WO2014128669A2/en active Application Filing
- 2014-02-24 PL PL14754772T patent/PL3019482T3/pl unknown
- 2014-02-24 ES ES14754772.3T patent/ES2694829T3/es active Active
- 2014-02-24 DK DK14754772.3T patent/DK3019482T3/en active
- 2014-02-24 US US14/784,708 patent/US9630932B2/en active Active
-
2017
- 2017-04-24 US US15/494,820 patent/US9937155B2/en active Active
- 2017-09-28 US US15/718,961 patent/US10080740B2/en active Active
-
2018
- 2018-09-07 US US16/124,578 patent/US20190105304A1/en not_active Abandoned
- 2018-11-07 CY CY181101172T patent/CY1120826T1/el unknown
- 2018-11-14 HR HRP20181908TT patent/HRP20181908T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9630932B2 (en) | 2017-04-25 |
| US20180021311A1 (en) | 2018-01-25 |
| US9937155B2 (en) | 2018-04-10 |
| EP3019482A2 (en) | 2016-05-18 |
| ES2694829T3 (es) | 2018-12-27 |
| US20170224663A1 (en) | 2017-08-10 |
| WO2014128669A2 (en) | 2014-08-28 |
| PL3019482T3 (pl) | 2019-02-28 |
| RS57962B1 (sr) | 2019-01-31 |
| WO2014128669A3 (en) | 2017-01-12 |
| EP3019482A4 (en) | 2017-05-10 |
| DK3019482T3 (en) | 2018-11-12 |
| EP3019482B1 (en) | 2018-08-15 |
| SI3019482T1 (sl) | 2018-12-31 |
| US20160200693A1 (en) | 2016-07-14 |
| US20190105304A1 (en) | 2019-04-11 |
| US10080740B2 (en) | 2018-09-25 |
| PT3019482T (pt) | 2018-11-28 |
| EP3417850A1 (en) | 2018-12-26 |
| HUE042032T2 (hu) | 2019-06-28 |
| HRP20181908T1 (hr) | 2019-01-11 |
| LT3019482T (lt) | 2018-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120826T1 (el) | Τριυποκατεστημενα παραγωγα βενζοτριαζολης ως αναστολεις διϋδροοροτικης οξυγενασης | |
| CY1122611T1 (el) | Ενωσεις πυραζολοπυριμιδινης ως αναστολεις κινασης | |
| CY1121625T1 (el) | Αναστολεις prmt5 και χρησεις αυτων | |
| CY1121433T1 (el) | Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4 | |
| CY1121265T1 (el) | Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου | |
| CY1118610T1 (el) | Αναστολεις κινασεων και η χρηση τους στη θεραπευτικη αγωγη του καρκινου | |
| CY1118993T1 (el) | Υποκατεστημενες ενωσεις τετραϋδροϊσοκινολινης ως αναστολεις τελεστη xiα | |
| CY1118464T1 (el) | Cetp αναστολεας τυπου συγχωνευμενης δικυκλικης οξαζολιδινονης | |
| CY1122046T1 (el) | Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων | |
| CY1117905T1 (el) | Αναστολεις πρωτεϊνικης κινασης | |
| CY1119678T1 (el) | Πυριμιδινονες ως αναστολεις τελεστη χια | |
| PH12016501338A1 (en) | Indazole compounds as irak4 inhibitors | |
| CY1124620T1 (el) | Οξυστερολες και μεθοδοι χρησης αυτων | |
| CY1118450T1 (el) | Διϋδροπυριδονη ρ1 ως αναστολεις του τελεστη χια | |
| CY1121444T1 (el) | Παραγωγα κιnoλonης ως αναστoλεις υποδοχεα αυξητικου παραγοντα ινοβλαστων | |
| PH12016500553A1 (en) | Substituted quinolizine derivatives useful as hiv integrase inhibitors | |
| MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
| UY36122A (es) | ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1? | |
| MX2017009449A (es) | Inhibidor jak. | |
| CR20140413A (es) | Inhibidores de serina/treonina cinasa | |
| CY1121677T1 (el) | Ενωσεις διμεθυλοβενζοϊκου οξεος | |
| MD20160106A2 (ro) | Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4 | |
| MX2015012431A (es) | Pirrol amida como inhibidores. | |
| PH12019501198A1 (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| CR20120397A (es) | Inhibidores del virus de la hepatitis c |